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Behavioral Risk Factor Surveillance System (BRFSS) for New Mexico (NM) in which 
self-reported health status was measured on a 5-point scale of poor to excellent. For 
the purpose of this study we dichotomized self-reported health into 2 categories: 
good (good, very good, and excellent) and poor (fair and poor). Propensity score 
model of 13 variables accounting for socioeconomic factors, disease status, and 
exercise behavior was used to match obese (body mass index (BMI) ≥ 30 kg/m2) indi-
viduals with non-obese (BMI < 30 kg/m2).We used the STATA command psmatch2 
to perform 1:1 nearest neighbor matching without replacement, and caliper width 
was set at 0.001. Adequacy of matching was assessed by estimating the standardized 
differences between obese and non-obese individuals for all variables. Self-reported 
health was compared between the 2 groups using the McNemar’s test for matched 
comparison. Results: We identified 2310 obese individuals (26%) and 6671 non-
obese individuals (74%) in the database. Obese individuals were significantly dif-
ferent from non-obese in nearly all baseline characteristics. After 1:1 propensity 
score matching (n = 3512), obese individuals were significantly more likely to report 
poor health compared to non-obese individuals (Odds ratio = 1.45, 95% confidence 
interval: 1.23-1.72, p< 0.001).All standardized differences between groups were < 10% 
suggesting and adequate matching. ConClusions: Among propensity-matched 
individuals, those with obesity are more likely to rate their health as poor compared 
to non-obese individuals. Continuing efforts are needed to fight obesity epidemic 
both locally and nationally to improve overall quality of life.
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objeCtives: To examine the effect of factor IX concentrate consumption on self/
parent-proxy reported health status among persons with hemophilia B. Methods: 
Data were obtained from the Hemophilia Utilization Group Study Part Vb (HUGS 
Vb), a prospective, multi-center observational study evaluating burden of illness 
among a US hemophilia B population who obtain care at Hemophilia Treatment 
Centers. Health status was assessed using a visual analogue scale (VAS) at initial 
interview and at two-year follow-up visits. A clinically meaningful improvement in 
health status was defined as an increase of > 7 in VAS score. Annual factor concen-
trate consumption was estimated using 2 years of dispensing records. Propensity 
score matching (PSM) was applied to adjust for potential selection bias between 
persons with high (≥ 5000 IU/kg/yr) and low (< 5000 IU/kg/yr) factor consumption. 
Age, disease severity, treatment regimen and bleeding frequency were included 
in the propensity score model. Results: After applying PSM, mean age in the 
high (n= 25, 20 severe) and low factor consumption (n= 25, 21 severe) groups were 
14.5±11.6 and 14.3±11.3, respectively. The average bleeding rates were 7.4±6.6 and 
7.2±7.8 per year correspondingly. The proportion of participants treated with pro-
phylactic therapy was 64% in both groups. On average, persons with high factor 
consumption reported greater (1.96±15.48) VAS score changes than those with low 
factor consumption. Among persons with VAS< 93 at baseline (n= 34), 14 participants 
reported a clinically meaningful improvement in VAS after 2 years. The propor-
tion of participants who reported a clinically meaningful improvement was greater 
among persons in the high consumption group than in the low consumption group 
(50% vs. 35%). ConClusions: Due to the small sample size, regression was not 
performed to show the independent relationship between health status and factor 
consumption. However, persons using > 5000 IU/kg/yr of factor tend to report greater 
improvement in health status.
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objeCtives: Improvements in health-related quality of life (HRQoL) with epratu-
zumab (a monoclonal antibody targeting CD22) have been reported in patients with 
systemic lupus erythematosus (SLE) in the ALLEVIATE trials from Week 12 to 4 
years. In the EMBLEM™ dose-ranging, phase IIb, randomized controlled trial in SLE, 
epratuzumab resulted in clinically-relevant improvements in disease activity. We 
report HRQoL data from EMBLEM™ and its open-label extension (OLE). Methods: 
In EMBLEM™, patients with moderate-to-severe SLE (≥ 1 BILAG 2004 A or ≥ 2 Bs) were 
randomized to placebo (PBO) or epratuzumab (cumulative dose [cd] 200, 800, 2400 or 
3600mg divided every other week, or 600mg every week), plus standard of care (SOC). 
Patients who completed 12 weeks or discontinued due to lack of efficacy after ≥ 8 
weeks were eligible for OLE (1200mg epratuzumab at Weeks 0,2 of 12-week cycles). 
HRQoL was assessed using Short Form-36 (SF-36) v2.0. Data are reported to the end 
of EMBLEM™ and OLE Weeks 48 and 108. Mean changes and % patients reporting 
improvements ≥ minimum clinically important differences (MCID) (increases from 
baseline ≥ 5.0-points in domain and ≥ 2.5-points in physical and mental compo-
nent scores [PCS and MCS]) are presented. Results: Mean PCS and MCS scores 
across all groups increased from baseline through EMBLEM™ Week 12, with greater 
increases in the PBO group. Longer epratuzumab treatment during OLE resulted 
in clinically meaningful changes in HRQoL vs EMBLEM™ baseline. Mean PCS/MCS 
scores were 34.2/36.1, 38.7/40.0, 40.1/41.6 and 40.5/40.9 at EMBLEM™ baseline, OLE 
screening, Week 48 and Week 108, respectively. At OLE Week 108 70.8% and 59.3% 
of patients reported improvements ≥ MCID in PCS and MCS scores. ConClusions: 
therapeutic areas (classified according to the ICD-10) and 67 different indications. 
The most represented therapeutic areas were neoplasms (28 products, 40.6%) and 
endocrine, nutritional and metabolic diseases (21 products, 30.4%). Out of the 69 
products, 14 had a PRO claim (20.3% – in comparison, for all EMA products, the 
percentage is 26.9%). PROs identified in the claims were assessing function (e.g., 
physical functioning), symptoms (e.g., pain) and quality of life (QOL). Corresponding 
therapeutic areas and indications were neoplasms (trabectedin, ofatumumab, 
ruxolitinib), endocrine diseases (aztreonam lysine, ivacaftor, tafamidis), nervous 
system diseases (stiripentol, rufinamide), blood diseases (eculizumab, icatibant), 
pulmonary arterial hypertension (bosentan monohydrate, ambrisentan), cryopyrin-
associated periodic syndromes (rilonacept), and severe pain (ziconotide). Within 
these 14 products, four have a QOL claim (28.6%): two for neoplasms [trabectedin 
(ovarian cancer) – no differences between treatment in QOL; and ruxolitinib (mye-
olofibrosis) - improvement of QOL], one in diseases of the blood [eculizumab (two 
indications: paroxysmal nocturnal haemoglobinuria and atypical haemolytic urae-
mic syndrome - improvement of QOL], and one in endocrine disease [tafadimis 
(amyloidosis) – improvement of QOL]. ConClusions: The number of PRO claims in 
orphan medicines is comparable to the number of PRO claims in all EMA products. 
Various concepts are assessed, with QOL representing almost 30% of the claims.
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objeCtives: To estimate direct and indirect costs associated with hand, foot and 
mouth disease (HFMD) in China. Methods: Data were obtained from a nation-
wide telephone survey of family member of patients with HFMD from Dec, 2013 
to Jan, 2014. Patients’ numbers were from national infection disease surveillance 
database. Patients were eligible for the survey if they aged from 6 months to 5 years, 
had lab-confirmed as EV71, CoxA16 or other Enterovirus infection and without any 
underlying disease. HFMD-related outpatient and inpatient utilization and costs 
and direct non-medical costs were recorded. Indirect costs resulting from produc-
tivity loss due to absenteeism were estimated using the average income in China. 
All costs were reported in 2012 US dollar using the exchange rate of 6.18 Chinese 
Yuan to 1 USD. Results: A total of 3500 patients were included with 34.3% female. 
The number of mild, severe and death cases were 2259(64.54%), 1170(33.43%) and 
71(2.03%). 2352(67.23%) of patients received inpatient treatment. The mean direct 
medical costs were $966. Inpatient costs were $904, accounting for 93.5% of direct 
medical costs. The rest were attributed to outpatient and medications purchased 
from retail pharmacies. Mean direct non-medical costs were $67, including $20 
nutrition costs and $47 transportation. Mean costs associated with productivity 
loss were $170 and $55 (urban and rural respectively). ConClusions: HFMD poses 
substantial economic burden to payers, patients and society. The majority of total 
costs are attributed to direct medical costs but indirect costs from productivity loss 
are also substantial.
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objeCtives: The purpose of this literature review was to identify existing patient 
reported outcome (PRO) instruments, instrument items, and concepts employed 
in studies of health-related quality of life (HRQoL) and PROs in anemia of ESRD. 
The results will aid the development of a PRO for the assessment of HRQoL in this 
therapeutic area. Methods: Relevant abstracts for inclusion were identified via 
a search in OVID (MEDLINE 1946 to present; EMBASE 1988 to present) using terms 
related to: anemia, HRQoL, PRO, ESRD, chronic kidney disease (CKD), and renal insuf-
ficiency. Results were limited to English-language, non-animal studies, and adult 
samples. Articles focusing on treatment effects and non-relevant diseases, confer-
ence abstracts and duplicate articles were excluded. Results: The search identified 
1764 abstracts. 1752 were excluded based on pre-specified criteria. Only 12 met the 
inclusion criteria. No ESRD anemia-specific PROs were identified. The most fre-
quently utilized PROs applied in ESRD anemia included the Kidney Disease Quality 
of Life and the Kidney Disease Quality of Life Short Form. Key concepts reflected 
direct patient experiences and disease impacts, and covered three domains: physi-
cal, mental/emotional, and social. Specific concepts within the domain of physical 
health included physical function, pain, fatigue, sleep disturbance, and sexual func-
tion. Concepts within the domain of mental/emotional health included emotional 
distress, cognitive effects, and satisfaction with life. Concepts within the domain 
of social health included ability or willingness to participate in social activities, and 
disease impacts on social relationships and work status. ConClusions: No PROs 
developed in ESRD-related anemia or published studies exploring HRQoL of anemic 
ESRD patients were found. The results of this literature review highlight the absence 
of in-depth qualitative examinations of patient experiences of ESRD-related anemia, 
as well as the lack of disease-specific PRO instruments. Relevant concepts identi-
fied may be useful to inform the development of ESRD anemia-specific PRO tools.
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objeCtives: Within New Mexico (NM) half of adults are either overweight or obese. 
Obesity is associated with low socioeconomic status, sedentary life style and several 
diseases; all pose a threat on general health. In order to rule out potential confound-
ing, we use propensity score matching to compare self-reported health of obese 
individuals with those of non-obese. Methods: We utilized data from the 2011 
